The definitive agreement, which is awaiting approval from Poland’s authorities, will enable the acquirer to expand its presence in the country by deploying the target company’s practitioners.
The transaction is expected to complete in Q4 2016.
Leap Therapeutics, an immuno-oncology company, has signed a definitive agreement to acquire biopharmaceutical firm, Macrocure, which will become a wholly-owned subsidiary of the acquirer, which in turn will become a public company upon completion of the transaction.
The acquisition will help the two companies to advance two first-in-class immuno-oncology monoclonal antibodies targeting aggressive cancers.
The acquisition results in Eckert & Ziegler gaining the latter’s customer base in Great Britain and Portugal, thereby strengthening its position in the European prostate grains market.